Ongoing and unsaid on oxaliplatin: the hope.

por Cvitkovic, E.
Publicado 1998

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity

por Serova, M, Bieche, I, Sablin, M-P, Pronk, G J, Vidaud, M, Cvitkovic, E, Faivre, S, Raymond, E
Publicado 2011

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer p...

por Bensmaïne, M A, Marty, M, Gramont, A de, Brienza, S, Lévi, F, Ducreux, M, François, E, Gamelin, E, Bleiberg, H, Cvitkovic, E
Publicado 2001

Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis.

por Janot, F., Klijanienko, J., Russo, A., Mamet, J. P., de Braud, F., El-Naggar, A. K., Pignon, J. P., Luboinski, B., Cvitkovic, E.
Publicado 1996

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells

por Serova, M, Galmarini, C M, Ghoul, A, Benhadji, K, Green, S R, Chiao, J, Faivre, S, Cvitkovic, E, Le Tourneau, C, Calvo, F, Raymond, E
Publicado 2007

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

por Benhadji, K A, Serova, M, Ghoul, A, Cvitkovic, E, Le Tourneau, C, Ogbourne, S M, Lokiec, F, Calvo, F, Hammel, P, Faivre, S, Raymond, E
Publicado 2008

Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

por Brain, E., Garrino, C., Misset, J. L., Carbonero, I. G., Itzhaki, M., Cvitkovic, E., Goldschmidt, E., Burki, F., Regensberg, C., Pappo, E., Hagipantelli, R., Musset, M.
Publicado 1997